Kuipers-Connarn, J. N., Pourzanjani, A., Bose, M., Modi, S., Stieglmaier, J., Murphy, A., . . . Upreti, V. V. (2025, August 5). Clinical Pharmacology Characterization and Dose Selection of Xaluritamig, a Next Generation XmAb® 2+1 T-Cell Engager, in Prostate Cancer Patients. Journal of clinical pharmacology. https://doi.org/10.1002/jcph.70074
Chicago Style (17th ed.) CitationKuipers-Connarn, Jamie N., Arya Pourzanjani, Maitreyee Bose, Saurabh Modi, Julia Stieglmaier, Alexis Murphy, Khamir Mehta, and Vijay V. Upreti. "Clinical Pharmacology Characterization and Dose Selection of Xaluritamig, a Next Generation XmAb® 2+1 T-Cell Engager, in Prostate Cancer Patients." Journal of Clinical Pharmacology 5 Aug. 2025. https://doi.org/10.1002/jcph.70074.
MLA (9th ed.) CitationKuipers-Connarn, Jamie N., et al. "Clinical Pharmacology Characterization and Dose Selection of Xaluritamig, a Next Generation XmAb® 2+1 T-Cell Engager, in Prostate Cancer Patients." Journal of Clinical Pharmacology, 5 Aug. 2025, https://doi.org/10.1002/jcph.70074.